Wednesday, February 04, 2015 8:44:42 AM
ARCA biopharma, Inc. (ABIO), a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods and compositions of the S-isomer formulation of GencaroTM (bucindolol hydrochloride). The patent (USP# 8946284), entitled “Methods and Compositions involving (S)-Bucindolol,” provides intellectual property protection in the United States for the use of S-isomer Gencaro (Gencaro substantially free of its R-stereoisomer) as a potential treatment for right ventricular heart failure, congestive heart failure, hypertension, angina, myocardial infarction, cardiac arrhythmia, mitral valve prolapse, hypertrophic obstructive cardiomyopathy, or acute dissecting aortic aneurysm.
“We are pleased with the USPTO’s issuance of this patent, which we believe broadens our intellectual property protection around Gencaro in multiple important cardiovascular disease indications which impact large patient populations globally,” said Michael R. Bristow, President and Chief Executive Officer of ARCA. “This patent is a result of ARCA’s continued focus on innovation in cardiovascular drug development. The S-isomer of Gencaro contains the high affinity beta-1 and beta-2 receptor-blocking action as well as nitric oxide generating activity. In GENETIC-AF, our on-going Phase 2B/3 clinical trial, we are evaluating racemic (contains both S and R isomers) Gencaro as a potential treatment for the prevention of atrial fibrillation in a pharmacogenetically defined heart failure population at high risk of developing recurrent atrial fibrillation.”
Recent ABIO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 09:57:33 PM
- ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split • GlobeNewswire Inc. • 08/29/2024 08:50:15 PM
- ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics • GlobeNewswire Inc. • 08/26/2024 11:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 08:35:36 PM
- ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics • GlobeNewswire Inc. • 08/23/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 06:23:17 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/16/2024 08:27:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:25:22 PM
- ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics • GlobeNewswire Inc. • 08/16/2024 08:15:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/15/2024 08:17:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 08:15:35 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/09/2024 12:35:20 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/01/2024 08:30:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:25:09 PM
- ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/01/2024 08:15:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/01/2024 08:10:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:05:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 02:50:20 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/25/2024 04:15:10 AM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 07/22/2024 09:17:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 11:38:10 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 11:10:32 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 07/09/2024 09:29:01 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 07/09/2024 09:04:50 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM